Pathology method for in-situ detection of expression of PD-L1 in tumor tissue
In situ staining using the PD-1-Fc fusion protein solves the specificity and cost issues of existing PD-L1 detection methods, enabling a simple and efficient detection of PD-L1 expression in tumor tissues.
Patent Information
- Application Number
- CN202410187026.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-02-20
- Publication Date
- 2024-11-01
AI Technical Summary
Existing PD-L1 detection methods suffer from low antibody specificity, cross-reactivity, and high cost, and are complex to operate, making it difficult to achieve efficient and convenient detection of PD-L1 expression in tumor tissues.
In situ staining was performed using the PD-1-Fc fusion protein. The fusion protein of the extracellular domain of PD-1 and Fc was used as an affinity probe to directly recognize the expression of PD-L1, avoiding antigen retrieval, simplifying the operation process, and improving staining specificity.
This approach achieves ease of operation and staining specificity in PD-L1 detection, reduces production costs, and improves detection efficiency and accuracy.
Smart Images

Figure CN118883802A_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the technical field of pathology, and in particular relates to a pathological method for in situ detection of PD-L1 expression in tumor tissue. Background Art
[0002] Cancer is a health problem, but with the rapid development of life sciences, in-depth research on the PD-1 / PD-L1 signaling pathway has provided new hope for conquering cancer. This pathway plays an important regulatory role in immune response, and tumors use its negative regulatory effect to develop.
[0003] Currently, clinical studies of monoclonal antibodies targeting the PD-1 / PD-L1 signaling pathway are ongoing, among which nivolumab and pembrolizumab have achieved significant therapeutic effects in patients with advanced non-small cell lung cancer. However, only about 20% of patients benefit, and this heterogeneity is related to whether the patient expresses PD-L1. Therefore, using PD-L1 as a biomarker to screen and treat patients is an effective way to achieve personalized immunotherapy.
[0004] A variety of markers have been found to predict the efficacy of PD-1 / PD-L1 inhibitors, such as PD-L1 expression level, MMR expression status, and TMB. Among them, the immunohistochemical detection of PD-L1 was studied the earliest and most thoroughly. Immunohistochemical detection is a commonly used method in pathological diagnosis. It locates, qualitatively, and quantitatively studies antigens in tissue cells through the specific binding and color development of labeled antibodies and antigens in tissues. PD-L1 detection is the most complex test in pathological immunohistochemistry, which requires systematic training of pathologists and technicians to ensure the quality control of PD-L1 detection.
[0005] At present, the methods for PD-L1 detection in China and abroad are almost all focused on antibodies against PD-L1, which are divided into polyclonal antibodies and monoclonal antibodies. Polyclonal antibodies have low specificity and will produce cross-reactions; monoclonal antibodies have strong specificity and high antibody yield. However, monoclonal antibodies also have some inherent defects, such as high price and quality issues. Summary of the invention
[0006] In view of the problems existing in the prior art, the present invention provides a pathological method for in situ detection of PD-L1 expression in tumor tissue, which avoids antigen repair and directly drips and stains after dewaxing, and has the advantages of being easier to operate. At the same time, it cleverly utilizes the natural receptor-ligand interaction, increases the specificity of staining, and solves the above-mentioned problems.
[0007] The present invention is achieved as follows: a pathological method for in situ detection of PD-L1 expression in tumor tissue, comprising the following steps: sequence synthesis and sequencing; PD-1-Fc plasmid construction: expression and identification of PD-1-Fc fusion protein: in situ staining of PD-L1, using PD-1-Fc fusion protein to perform in situ staining in paraffin tissues of various collected tumors.
[0008] As a preferred embodiment of the present invention, the PD-1-Fc plasmid construction includes the following steps: PD-1 gene optimization and synthesis; preparation of competent cells GH2; PD-1-Fc plasmid construction.
[0009] As a preferred embodiment of the present invention, the steps of optimizing and synthesizing the PD-1 gene include: intercepting the extracellular segment sequence in the human PD-1 gene sequence, including the start codon and the signal peptide, but without the stop codon; according to the degeneracy of the genetic codon, performing mutation optimization on the sequence to meet the requirements of the Cricetulus griseus (CHO) cell eukaryotic expression system for expressing AP fusion protein, and not containing commonly used restriction endonuclease sites, such as BamHI, SacI, KpnI, SmaI, PstI, HindIII, BglII; inserting the KOZAK (5'-ACCCCGCCCGCCACC-3') sequence before the start codon ATG at the 5' end of the optimized PD-1 sequence, and inserting HindIII (5'-AAGCTT-3') restriction endonuclease sites at the 5' end of the PD-1 sequence and BglII (5'-AGATCT-3') restriction endonuclease sites at the 3' end, so as to insert the PD-1 sequence into the Fc-Tag vector.
[0010] As preferred of the present invention, the preparation of competent cells GH2 includes the following steps: taking out Escherichia coli GH2 from -80°C and streaking it on a non-resistant LB solid culture medium, culturing it in an adjustable constant temperature incubator at 37°C overnight, picking a single colony the next day and inoculating it in a 15mL centrifuge tube containing 5mL non-resistant LB liquid culture medium, and culturing it on a constant temperature shaking shaker at 37°C and 220rpm for 16h; taking 3mL of bacterial solution and inoculating it in 100mL non-resistant LB liquid culture medium, culturing it on a constant temperature shaking shaker at 37°C and 220rpm until the absorbance of the bacterial solution at 550nm is 0.5-0.6, cooling it on ice for 10min, centrifuging it at 4°C and 4000rpm for 10min, and discarding the supernatant; adding 7.5mL of pre-cooled 0.1M MgCl2 solution to stagnate the bacterial solution, resuspending it and centrifuging it at 4°C and 4000rpm for 10min, and discarding the supernatant; adding 5mL of pre-cooled 0.1M The bacterial liquid was stagnated with CaCl2 solution, and after resuspending, it was ice-bathed for 20 minutes, and then centrifuged at 4°C and 4000rpm for 10 minutes, and the supernatant was discarded; 17.2mL of pre-cooled 0.1M CaCl2 solution was added, and after ice-bathed for 30 minutes, 5mL of pre-cooled 50% glycerol was added, and after pipetting and mixing, 200μL / tube was dispensed into sterile 0.5mL centrifuge tubes, and immediately plunged into liquid nitrogen, and stored at -80°C after it was completely frozen.
[0011] As preferred embodiment of the present invention, the expression of PD-1-Fc fusion protein includes the following steps: CHO host cell subculture; 293T host cell subculture; plasmid stable transfection into CHO (dhfr-) cells and transient transfection into 293T cells; PD-1-Fc high expression cell line screening; serum-free acclimation culture of PD-1-Fc high expression cell line; PD-1-Fc fusion protein production; PD-1-Fc fusion protein Protein A affinity chromatography purification; BCA method determination of PD-1-Fc purified protein concentration; SEC-HPLC detection of PD-1-Fc product purity and determination of molecular weight and in situ staining of tumor tissue.
[0012] As a preferred embodiment of the present invention, the step of subculturing the CHO host cells comprises: culturing the CHO host cells in IMDM serum-containing medium; and performing CHO (dhfr-) cell recovery, subculturing and plating.
[0013] As a preferred embodiment of the present invention, the steps of stably transfecting the plasmid into CHO (dhfr-) cells and transiently transfecting into 293T cells include: observing the growth of the cells in the 6-well plate, aspirating 1 mL of the old culture medium; preheating the serum-free IMDM culture medium to 37°C, placing the FuGENE6 transfection reagent at room temperature, and flicking with fingers to mix; taking a 1.5 mL sterile centrifuge tube, adding 600 μL of serum-free IMDM culture medium and 18 μL of FuGENE6 to it, flicking with fingers to mix, and then placing at room temperature for 5 minutes, and then evenly dividing it into 6 1.5 mL sterile centrifuge tubes, and adding 3 of them to the centrifuge tubes. Add 1 μg of pPD-1-Fc plasmid to be transfected to each tube, and the remaining 3 tubes without plasmid are used as the control group. After flicking with fingers to mix, let it stand at room temperature for 20 minutes; add the plasmid mixture to 6-well plates respectively. One tube of the mixture containing pPD-1-Fc or not containing plasmid is added to the six-well plate paved with CHO (dhfr-), and the other tube is added to the six-well plate paved with 293T. After shaking up and down and left and right crosswise to mix, put the 6-well plate back into the incubator and culture for 72 hours. After 72 hours, collect the culture medium of transiently transfected 293T to detect the expression of fusion protein to determine whether the target protein is secreted in the culture medium.
[0014] As a preferred embodiment of the present invention, the step of serum-free acclimation culture of the PD-1-Fc high-expressing cell line includes: taking the PD-1-Fc high-expressing monoclonal cells screened under the condition of adding MTX pressure to 500nM and culturing them in a P100 cell culture dish, and when the cell growth density reaches 80% to 90% and the cell state is good, retaining 1mL of the original serum IMDM culture medium in the P100 culture dish, adding 9mL of serum-free culture medium SFM, and reducing the proportion of FBS in the culture medium to 1%; culturing in a 37°C cell incubator for 24h, and observing the cell suspension and cell state , retain 1mL of the original culture medium again, add 9mL SFM, at this time the FBS ratio in the culture medium is reduced to 0.1%; culture in a 37℃ cell incubator for 24h, shake the cells and culture medium in the culture dish, take 9mL to a sterile 15mL centrifuge tube, take 1mL from it for Vi-cell counting, and record the cell number and cell activity, adjust the cell number of the remaining cells to 0.25-0.5×106 / mL, 6mL / 50mL centrifuge tube, place it in a 37℃, 5% CO2 incubator shaker at 180rpm / min for suspension culture; repeat the above operation. Note that during the serum-free acclimation culture process, the P100 culture dish always maintains a 500Nm MTX pressure, and the suspended cultured cells reduce the MTX to the optimal concentration according to the actual situation of the cell adaptation to MTX after suspension. The cells in the centrifuge tube need to be counted every day. If the cell density reaches 2×106 cells / mL, pass it to 0.25-0.5×106 cells / mL. When the cell number can double normally every day and the cell activity is good, the culture can be continued in SFM. When the cell density reaches about 2×106 cells / mL, adjust the cell number to 10×106 cells / mL, add 7.5% dimethyl sulfoxide (DMSO), pipette and mix, 10×106 cells / mL / tube, and transfer to liquid nitrogen for storage.
[0015] As a preferred method of the present invention, in situ staining of tumor tissues comprises the following steps: in situ staining of paraffin sections of various tumor tissues with the target protein obtained by Protein A affinity chromatography purification, the main steps are as follows:
[0016] 1) Heat the paraffin sections in a 65°C incubator for 2 hours, then dewax in xylene for 15 minutes twice; then soak in 100%, 95%, 80%, and 70% alcohol for 2 minutes each; and wash with distilled water for 5 minutes twice.
[0017] 2) Treat the slices with 3% hydrogen peroxide (room temperature) for 25 min to block the action of endogenous catalase → wash thoroughly with distilled water (on a shaker) → wash with PBS for 5 min × 2 times;
[0018] 3) Directly add PD-1-Fc (2u / mL) onto the sliced tissue, incubate in a humidified box at 37°C for 30 min → rinse the tissue slices at room temperature with PBS for 5 min × 2 times;
[0019] 4) Add HRP Polymer (enzyme-labeled secondary antibody binds to Fc), incubate at room temperature for 30 minutes → rinse tissue sections in PBS at room temperature for 5 minutes × 2 times;
[0020] 5) DAB was evenly dropped on the coverslips of each well and placed in a 37°C oven for reaction;
[0021] 6) When the coverslips of the experimental group are brown-yellow and the cell surface is stained to a certain extent under a microscope, wash away the residual DAB on the coverslips with purified water; seal the slides with neutral gum and observe under a light microscope.
[0022] Compared with the prior art, the present invention has the following beneficial effects:
[0023] 1. In the present invention, Fc-Tag technology is to fuse a certain biologically active functional protein molecule with an Fc fragment (Fc segment of an antibody) using genetic engineering and other technologies to produce a new type of dimeric protein. The functional protein can be a soluble ligand (or receptor) molecule or other active substances (such as cytokines) that can bind to endogenous receptors (or ligands). The fusion protein obtained using FC-Tag technology has the advantages of retaining the biological activity of the functional protein molecule, having some properties of antibodies and being easy to purify. In the present invention, this tag is fully utilized to produce a fusion protein of the extracellular segment of PD-1 and Fc.
[0024] 2. The fusion protein of the extracellular segment of PD-1 and Fc is used as an affinity probe to directly identify the expression of PD-L1, cleverly utilizing the natural receptor-ligand interaction, thus increasing the specificity of staining.
[0025] 3. The Fc tag promotes protein dimerization, thereby enhancing protein stability and facilitating purification. The fusion protein produced by this tag has the advantages of low production cost and high production efficiency.
[0026] 4. Compared with the existing immunohistochemistry method, this method avoids antigen repair and is directly dripped and stained after dewaxing, which is easier to operate. BRIEF DESCRIPTION OF THE DRAWINGS
[0027] Figure 1 It is the comparison result of the optimized mutated PD-1 sequence and the original PD-1 sequence provided in the embodiment of the present invention and the sequence table after synthesis;
[0028] Figure 2 is a colony PCR reaction condition diagram provided by an embodiment of the present invention;
[0029] Figure 3 is a schematic diagram of the structure of the pPD-1-Fc plasmid provided in an embodiment of the present invention;
[0030] Figure 4 This is a pPD-1-Fc plasmid enzyme digestion identification diagram provided in an embodiment of the present invention, wherein lane 1: DNA marker, lane 2: pPD-1-Fc without enzyme digestion, lane 3: pPD-1-Fc after enzyme digestion;
[0031] Figure 5 is a feed supplement method table provided in an embodiment of the present invention;
[0032] Figure 6 The PD-1-Fc feeding optimization provided in the embodiment of the present invention: cell growth curve (A) and activity curve (B) of PD-1-Fc under two feeding conditions, SDS-PAGE comparison of the yield of PD-1-Fc under two feeding conditions (C) (-me), SDS-PAGE comparison of the yield of PD-1-Fc under two feeding conditions (D) (+me);
[0033] Figure 7 PD-1-Fc Process in SFM with Logicfeed2# provided in an embodiment of the present invention: cell growth curve (A) and activity curve (B) during PD-1-Fc Process, change in target protein yield during PD-1-Fc Process detection by SDS-PAGE (-me) (C), change in target protein yield during PD-1-Fc Process detection by SDS-PAGE (+me) (D);
[0034] Figure 8 The PD-1-Fc and PD-L1-Fc Protein A affinity chromatography purification and post-purification detection provided in the embodiments of the present invention, wherein A represents the purification chromatogram of PD-1-Fc Protein A, the arrow in the figure indicates the elution peak of the target protein, and B represents the purification effect of PD-1-Fc detected by SDS-PAGE;
[0035] Fig. 9 It is a BSA concentration standard curve reaction system diagram provided in an embodiment of the present invention;
[0036] Fig.10 This is a graph of the molecular weight and purity of PD-1-Fc analyzed by SEC-HPLC provided in an embodiment of the present invention, wherein A represents a molecular weight standard, and B represents SEC-HPLC detection of PD-1-Fc;
[0037] Fig.11These are representative diagrams of high and low PD-L1 expression in lung cancer provided by the embodiments of the present invention: A and C are PD-1-Fc staining and HE staining of lung cancer with high PD-L1 expression, respectively; B and D are PD-1-Fc staining and HE staining of lung cancer with low PD-L1 expression, respectively;
[0038] Fig.12 These are representative images of liver cancer with high and low PD-L1 expression provided by the embodiments of the present invention: A and C are PD-1-Fc staining and HE staining of liver cancer with high PD-L1 expression, respectively; B and D are PD-1-Fc staining and HE staining of liver cancer with low PD-L1 expression, respectively;
[0039] Fig.13 These are representative images of colon cancer with high and low PD-L1 expression provided by the embodiments of the present invention: A and C are PD-1-Fc staining and HE staining of colon cancer with high PD-L1 expression, respectively; B and D are PD-1-Fc staining and HE staining of colon cancer with low PD-L1 expression, respectively;
[0040] Fig.14 These are representative images of ovarian cancer with high and low PD-L1 expression provided by the embodiments of the present invention: A and C are PD-1-Fc staining and HE staining of ovarian cancer with high PD-L1 expression, respectively; B and D are PD-1-Fc staining and HE staining of ovarian cancer with low PD-L1 expression, respectively;
[0041] Fig.15 These are representative diagrams of breast cancer with high and low PD-L1 expression provided by the embodiments of the present invention: A and C are PD-1-Fc staining and HE staining of breast cancer with high PD-L1 expression, respectively; B and D are PD-1-Fc staining and HE staining of breast cancer with low PD-L1 expression, respectively. DETAILED DESCRIPTION
[0042] In order to further understand the content, features and effects of the present invention, the following embodiments are given as examples and described in detail with reference to the accompanying drawings.
[0043] The structure of the present invention is described in detail below in conjunction with the accompanying drawings.
[0044] An embodiment of the present invention provides a pathological method for in situ detection of PD-L1 expression in tumor tissue, comprising the following steps:
[0045] 1. Construction of PD-1-Fc plasmid
[0046] 1.1PD-1 gene optimization and synthesis
[0047] In this experiment, the extracellular segment of the human PD-1 gene sequence was intercepted, including the start codon and signal peptide, but without the stop codon. According to the degeneracy of the genetic codon, the sequence was mutated and optimized to meet the requirements of the Cricetulusgriseus (CHO) cell eukaryotic expression system for expressing AP fusion protein, and it does not contain commonly used restriction endonuclease sites, such as BamHI, SacI, KpnI, SmaI, PstI, HindIII, BglII, etc. In addition, the KOZAK (5'-ACCCCGCCCGCCACC-3') sequence was inserted before the start codon ATG at the 5' end of the optimized PD-1 sequence, and the restriction endonuclease sites of HindⅢ (5'-AAGCTT-3') and BglⅡ (5'-AGATCT-3') were inserted at the 5' end of the PD-1 sequence and at the 3' end, so that the PD-1 sequence can be inserted into the Fc-Tag vector. The comparison results of the optimized mutated PD-1 sequence and the original PD-1 sequence and the synthesized sequence are shown in Figure 1. Figure 1 shown.
[0048] 1.2 Preparation of competent cells GH2
[0049] Take out E. coli GH2 from -80℃ and streak it on the LB solid medium without resistance, and culture it in an adjustable constant temperature incubator at 37℃ overnight. On the next day, pick a single colony and inoculate it in a 15mL centrifuge tube containing 5mL of LB liquid medium without resistance, and culture it in a constant temperature shaking shaker at 37℃ and 220rpm for 16h. Take another 3mL of bacterial solution and inoculate it in 100mL of LB liquid medium without resistance, and culture it in a constant temperature shaking shaker at 37℃ and 220rpm until the absorbance of the bacterial solution at 550nm is 0.5-0.6. After cooling on ice for 10min, centrifuge it at 4℃ and 4000rpm for 10min, and discard the supernatant; add 7.5mL of pre-cooled 0.1M MgCl2 solution to stop the bacterial solution, resuspend it and centrifuge it at 4℃ and 4000rpm for 10min, and discard the supernatant; then add 5mL of pre-cooled 0.1M The bacterial liquid was stagnated with CaCl2 solution, and then ice-bathed for 20 minutes after resuspending, and then centrifuged at 4°C and 4000rpm for 10 minutes, and the supernatant was discarded; then 17.2mL of pre-cooled 0.1M CaCl2 solution was added, and ice-bathed for 30 minutes, and then 5mL of pre-cooled 50% glycerol was added. After gently blowing and mixing, 200μL / tube was dispensed into sterile 0.5mL centrifuge tubes, and immediately plunged into liquid nitrogen, and stored at -80°C after it was completely frozen.
[0050] 1.3 PD-1-Fc plasmid construction
[0051] The pUC57-PD-1 glycerol bacteria obtained after gene synthesis were streaked on LB solid medium with ampicillin resistance (A+) and tetracycline resistance (T+), cultured overnight at 37°C in an adjustable constant temperature incubator, and a single colony was picked and inoculated in a 15mL centrifuge tube containing 5mL of non-resistant LB liquid medium the next day, and cultured for 16h at 37°C and 220rpm in a constant temperature shaking shaker. Before plasmid extraction, the strain was preserved, added to a 1.5mL centrifuge tube at a ratio of 50% glycerol: bacterial solution = 3:1, mixed (50% glycerol 300μL, bacterial solution 100μL), sealed with a sealing film, and stored at -80°C.
[0052] Centrifuge the remaining bacterial solution at 13400rpm for 1min in a 1.5mL centrifuge tube and discard the supernatant; then add 250mL solution / RNAse A (Omega) and vortex to resuspend the bacterial solution, then add 250μL SolutionⅡ to the above mixture and gently invert 4 to 6 times. This step should not exceed 5min; continue to add 350μL SolutionⅢ, gently invert several times until a white flocculent precipitate is formed, and then centrifuge at 13400rpm for 10min; transfer the upper clear liquid to a HiBind DNA binding column with a 2mL collection tube, centrifuge at 13400rpm for 1min, discard the filtrate in the collection tube, and re-install it with the HiBind DNA binding column; add 500μL HB Buffer, centrifuge at 13200rpm for 1min, discard the filtrate in the collection tube, and re-install it with the HiBind DNA binding column; add 700μL Wash Buffer, 13400rpm, 1min chamber centrifugation, discard the filtrate in the collection tube, and reassemble it with the HiBind DNA binding column, repeat this step once; install the HiBind DNA binding column on the collection tube, spin at 13400rpm for 2min, open the lid and let it air dry for 5min to evaporate the ethanol in it; then install the HiBind DNA binding column in a clean 1.5mL centrifuge tube, add 50μL of 65℃ preheated sterile water, centrifuge at 13200rpm, 1min, elute the DNA; measure the OD260 of the plasmid by UV spectrophotometer and calculate the concentration of the plasmid by the ratio of OD260 / OD280;
[0053] Take 1 μg of the obtained PD-1 plasmid and add it to a PCR tube, add HindIII and BglII restriction endonucleases, 10×KBuffer, and then add sterile water to make up to 50 μL of the reaction system, and perform double enzyme digestion in a 37°C constant temperature water bath for 2 hours. The enzyme digestion system is as follows:
[0054]
[0055]
[0056] The digestion products were separated by 2% agarose gel electrophoresis, and then the PD-1 (522 bp) and PD-L1 (747 bp) target band gels were cut with a blade under the irradiation of an ultraviolet analyzer and placed in a sterile 1.5 mL centrifuge tube. The PD-1 target fragment was recovered according to the instructions of the Omega gel recovery kit: the target band gel was placed in a sterile 1.5 mL centrifuge tube and weighed (in milligrams), and Binding buffer was added at a ratio of 1:1, and the mixture was placed in a 60°C water bath until it was completely melted; then the liquid was transferred to a HiBind column, centrifuged at 13400 rpm for 1 min, and the filtrate was discarded; then 700 μL SPW buffer was added to the HiBind column, and after standing at room temperature for 2 to 3 minutes, the column was centrifuged at 13400 rpm for 1 min, and the filtrate was discarded, and this step was repeated once; then the column was spun at 13400 rpm for 2 minutes; then the HiBind column was transferred to a 1.5 mL centrifuge tube, and 20 μL Preheat sterilized water at 60℃, centrifuge at 13400rpm for 1min, repeat the operation with 10μL preheated sterilized water at 60℃, collect the filtrate as the DNA solution, and then use agarose gel electrophoresis to detect whether the target fragment is successfully recovered. At the same time, take 1μg of pFc-Tag vector, add HindIII and BglII restriction endonucleases, 10×K Buffer, and add sterilized water to make up to 20μL of the reaction system, perform double enzyme digestion in a 37℃ constant temperature water bath, the reaction time is 2h, and the enzyme digestion system is as follows:
[0057] Sterilized water 11.2μL 10×Kbuffer 2μL PD-1 plasmid (1 μg) 4.8μL HindIII 1μL BglII 1μL Total 20μL
[0058] Add sterile water to the above Fc-Tag enzyme cleavage product to a total volume of 30 μL, then add an equal volume of phenol / chloroform mixture (phenol 3:1 chloroform), vortex oscillation for 15 seconds, ice bath for 5 minutes, centrifuge at 4°C 13200rpm, 5 minutes, carefully pipette the supernatant into a new sterilized 0.5mL centrifuge tube; add 3 μL 3M sodium acetate solution and 5 μL 10mg / ml glycogen, flick with fingers to mix, then add 180 μL pre-cooled anhydrous ethanol, vortex oscillation for 15 seconds, and place at -80°C for 2 hours; then, discard the supernatant; then carefully adhere to the wall and add 200 μL pre-cooled 85% ethanol solution, ice bath for 5 minutes, centrifuge at 4°C 13200rpm, 1 minute, discard the supernatant, open the lid and stand on ice for more than 1 minute to allow the ethanol to evaporate; then add 30 μL sterile water to dissolve the precipitate. The gel-recovered fragment of PD-1 and the purified product of Fc-Tag vector obtained by phenol / chloroform purification were added to the ligation system at a volume ratio of 16:1. The target fragment and the vector were ligated overnight at 16°C using T4 ligase (Takara). The ligation system is as follows:
[0059] 10×T4ligasebuffer 2μL AP-Tag digestion and purification 1μL T4ligase 1μL PD-1 glue recovery products 16μL Total 20μL
[0060] Take out 200 μl of E.ColiGH2 competent cells from the -80°C refrigerator and thaw on ice; after it is completely thawed, add 20 μL of the ligation product, mix it by pipetting, and then place it in an ice bath for 30-60 minutes; heat shock the mixture in a 42°C water bath for 90 seconds, and then place it in an ice bath for 3 minutes; add 800 μl of LB liquid culture medium without resistance, and culture it in a constant temperature shaking shaker at 37°C and 220 rpm for 1 hour; take out the bacterial solution, centrifuge it at 5000 rpm for 5 minutes, discard 800 μL of the supernatant, resuspend the bacteria with the remaining supernatant, and then evenly apply it on the LB (A+, T+) double-antibody solid culture plate, and culture it upside down at 37°C in an adjustable constant temperature incubator for 16-18 hours.
[0061] Take 30μL of bacterial lysate and add it to a 0.5mL centrifuge tube; then use a sterile gun tip to stick a small amount of bacterial monoclonal, put it into the bacterial lysate and blow it repeatedly to mix; then put it in boiling water for 5 minutes, take it out and centrifuge it at 13200rpm for 2 minutes, and take 1μL of supernatant as a template for colony PCR; the upstream primer uses the primer L-Fc on the pFc-Tag vector: 5'-GAACCCACTGCTTACTGGCT-3', and the downstream primer uses the primer R-Fc on the pFc-Tag vector: 5'-TCAGGGTCTTCGTGGCTCACG-3', which are the sequences on the Fc-Tag vector located upstream and downstream of the PD-1 insertion point. .
[0062] Colony PCR reaction system (10 μL):
[0063] Sterilized water 5.5μL 10xPCR buffer 1μL dNTP 0.4μL r-Taq 0.1μL L-AP 1μL R-AP 1 PD-1 / PD-L1 Template 1 Total 10μL
[0064] Colony PCR reaction conditions are as follows Figure 2 As shown:
[0065] The PCR products were separated by 2% agarose gel electrophoresis. The target bands at around 500 bp for PD-1-Fc and around 750 bp for PD-L1-Fc were regarded as positive clones. A small amount of the bacterial monoclonal colonies were streaked on the LB (A+, T+) double-antibody solid culture plate with a sterile gun tip, and cultured in an adjustable constant temperature incubator at 37°C for 16 to 18 hours; then a single clone was picked from the culture dish and inoculated into LB (A+, T+) double-antibody liquid culture medium for expansion culture, and cultured overnight in a constant temperature shaking incubator at 37°C and 220 rpm; then the plasmid was extracted according to the method provided by Omega's plasmid extraction kit.
[0066] Take 1 μg of the extracted pPD-1-Fc plasmid, add HindIII and BglII restriction endonucleases, 10×K Buffer, and then add sterile water to make up to 20 μL of the reaction system, and perform double enzyme digestion in a 37°C constant temperature water bath for 2 hours. The digestion products are separated by 2% agarose gel electrophoresis, and whether the bacterial clone is positive is further determined by whether the target band of known size is cut out, and the plasmid judged to be positive is sent for gene sequencing. The digestion system is as follows:
[0067]
[0068]
[0069] The PD-1 / PD-L1 fragment obtained by optimized synthesis, enzyme digestion, and gel recovery purification was inserted into the Fc-Tag vector through the two enzyme sites of HindⅢ and BglⅡ to construct the expression plasmid pPD-1-Fc / pPD-L1-Fc as shown in Figure 3 shown.
[0070] The pPD-1-Fc plasmid constructed above was double-digested with HindIII and BglII, and the digested products were separated by agarose gel electrophoresis to identify the correctness of its construction. The digestion identification results are as follows: Figure 4 As shown, pPD-1-Fc was digested to obtain a PD-1 target gene fragment of about 500 bp (theoretical size is 522 bp), indicating that the expression vector was constructed correctly.
[0071] 2. PD-1-Fc fusion protein expression
[0072] 2.1. CHO host cell subculture
[0073] CHO host cells are cultured in IMDM serum medium. First, we need to prepare IMDM medium. The operating procedures for preparing IMDM medium are as follows: First, soak the required 17# plastic tubes and glass bottles in CIP for at least 4 hours at least one day in advance, then rinse the measuring cylinders, beakers, magnetic stirring rotors, glass bottles and 17# plastic tubes required for liquid preparation with WFI, wrap them with tin foil and sterilize them in an autoclave at 121℃ for 30 minutes. After sterilization, put the measuring cylinders, beakers, magnetic stirring rotors, glass bottles, 17# plastic tubes, P20 and peristaltic pumps in the clean bench in advance and irradiate them with ultraviolet light for at least 15 minutes. Calculate the required amount of medicine according to the actual required liquid preparation volume, and fill in the corresponding data in the liquid preparation record table of the required reagents. Before preparation, add WFI that accounts for 80% of the total volume of the culture medium, then weigh and dissolve each drug one by one according to the formula. After the drug is completely dissolved, measure the pH and check whether it is 7.0. After adjusting the pH, use WFI to make up to the required volume. Continue to stir evenly and filter with P20 in a clean bench. Seal with sealing film and store at 4°C.
[0074] Then, CHO (dhfr-) cells were revived, subcultured and plated. The specific operation process is as follows:
[0075] 1) Take out a 40 mL tube of fetal bovine serum (FBS) and a tube of 10 mg / mL ciprofloxacin (cipro) from -20℃ and thaw naturally; take a 400 mL bottle of IMDM medium, add 200 μL of cipro (the final concentration of cipro is 5 μg / mL), shake well, and use a pipette to take out 40 mL of IMDM medium without serum and place it in a 50 mL centrifuge tube in preparation for transfection; add 40 mL of FBS to the remaining medium and shake well; use a pipette to take out 200 mL of IMDM with FBS and cipro and put it into another pre-sterilized glass bottle, add 4 mL of 50×HT, mix well; then store them at 4℃.
[0076] 2) Use a pipette to pipette 10 mL of IMDM medium pre-added with FBS, cipro, and HT into a P100 culture dish, and adjust the temperature of the adjustable constant temperature water bath to 37°C in advance.
[0077] 3) Take a GH-CHO (dhfr-) cell from the liquid nitrogen tank, and put it into a 37°C water bath and shake it quickly until it melts according to the principle of slow freezing and fast thawing. Then, use a pipette to draw 1 mL of IMDM medium into a 15 mL centrifuge tube in an ultra-clean workbench, and put the thawed cells into it and blow them evenly with a pipette. Then, centrifuge at 1500 rpm for 2 min, discard the medium, and then aspirate 4 mL of medium from P100, blow the cells evenly, and add them to the P100 culture dish. Shake the cells in the P100 by shaking them up and down and left and right, and then put them into a 37°C incubator with 5% CO2 for 2 days;
[0078] 4) CHO (dhfr-) cell passaging: Use a vacuum pump to suck away the culture medium in p100, then use 4 mL of sterile PBS to wash away the remaining culture medium in P100 and suck it away; then add 1 mL of trypsin, shake gently and place in a 37°C incubator to digest the cells, and observe under a microscope from time to time until the cells become round and slightly flow, then use 3 mL of new IMDM culture medium with serum to terminate the digestion reaction; use a pipette to blow the cells apart and transfer them to a sterile 15 mL centrifuge tube, centrifuge at 1500 rpm for 2 min; carefully suck away the supernatant with a vacuum pump, add 4 mL of new IMDM (+HT) culture medium with serum to resuspend the cells, after completely blowing and mixing, aspirate 1 mL of the cell suspension and place it in a p100 culture dish, and add 9 mL of new IMDM (+HT) culture medium with serum to it, shake the cells in P100 by shaking them up and down, left and right, and place them in a 37°C incubator with 5% CO2 for two days;
[0079] 5) Plating: After digesting the cells as described above, count them using a Vi-CELL cell counter and adjust the cell density to 0.1×106 cells / mL. Plate the cells at 2 mL / well in a 6-well plate and shake the cells evenly by moving them up and down and left and right in a cross motion. Culture the cells in a 37°C incubator with 5% CO2 overnight to allow the cells to grow completely attached to the wall.
[0080] 2.2.293T host cell subculture
[0081] 293T host cells are cultured in DMEM serum medium. First, we need to prepare DMEM medium. The operating procedures for preparing DMEM medium are the same as those for preparing IMDE medium. The only difference is that it is prepared according to the preparation table of DMED medium. Then, it is filtered with P20 in the clean bench, sealed with sealing film and stored at 4°C.
[0082] Then, 293T cells were revived, subcultured and plated. The specific operation procedures were consistent with those of the above CHO (dhfr-) cells, and then plated according to the above CHO (dhfr-) plating method.
[0083] 2.3. Stable transfection of plasmids into CHO (dhfr-) cells and transient transfection into 293T cells
[0084] Observe the growth of cells in the 6-well plate and remove 1 mL of old culture medium. Preheat serum-free IMDM culture medium to 37°C, place FuGENE6 transfection reagent at room temperature, and flick with fingers to mix; take a 1.5 mL sterile centrifuge tube, add 600 μL serum-free IMDM culture medium and 18 μL FuGENE6 to it, flick with fingers to mix, and place at room temperature for 5 minutes, then divide it evenly into 6 1.5 mL sterile centrifuge tubes, add 1 μg of pPD-1-Fc plasmid to be transfected to each of 3 centrifuge tubes, and do not add plasmid to the remaining 3 tubes as controls Group, flick with fingers to mix, and let stand at room temperature for 20 minutes; add the plasmid mixture into 6-well plates respectively, one tube of the mixture containing pPD-1-Fc or not containing plasmid is added into the 6-well plate paved with CHO (dhfr-), and the other tube is added into the 6-well plate paved with 293T. After shaking up and down and left and right crosswise to mix, put the 6-well plate back into the incubator and culture for 72 hours. After 72 hours, collect the culture medium of transiently transfected 293T to detect the expression of fusion protein, so as to judge whether the target protein is secreted in the culture medium.
[0085] The secreted PD-1-Fc fusion protein was detected by ELISA. The specific steps are as follows:
[0086] Take a clean detachable ELISA plate, take out a tube of 1mg / mL proteinA from -80℃ and thaw it naturally. After thawing, dilute it to 5ug / ml with 0.2μm filtered PBS, then add 100μL / well to the ELISA plate, incubate at 37℃ in the dark for 90min or coat overnight at 4℃; after coating, wash the ELISA plate with 0.05% PBST, 150μL / well, repeat the washing three times, and turn the ELISA plate upside down to dry the waste liquid; then use 1mg / mL BSA in PBS, 100μL / well to block in a 37℃ constant temperature box for 1h; after blocking, wash the ELISA plate with 0.05% PBST, 150μL / well, repeat the washing three times, and turn the ELISA plate upside down to dry the waste liquid; take 10μL of PD-1-Fc cell culture medium in the 96-well plate and add it to the ELISA plate, and then add 90μL 0.2μm filtered PBS, put it in a 37℃ constant temperature incubator for incubation for 1h, after the incubation, wash the ELISA plate with 0.05% PBST, 150μL / well, repeat the washing three times, and turn the ELISA plate upside down to dry the waste liquid; PD-1-Fc was diluted to 2U / mL with 1mg / mL BSA in PBS, 100μL / well was added to the corresponding ELISA plate, and incubated in a 37℃ constant temperature incubator for 1h; after the incubation, wash the ELISA plate with 0.05% PBST, 150μL / well, repeat the washing twice, and then wash it once with 1×PCR buffer. After washing, turn the ELISA plate upside down to dry the waste liquid; 2×Reagent A was diluted to 1× with WFI, 100μL / well was used for color development and timing, and when the absorbance value at 405nm was about 1, 0.5M The reaction was terminated by adding NaOH, 100 μL / well, and the absorbance at 405 nm was read using a microplate reader. The higher the absorbance value, the higher the yield of PD-1-Fc protein.
[0087] 2.4. Screening of cell lines with high expression of PD-1-Fc
[0088] The host cells in this experiment are Chinese hamster ovary cells (CHO (dhfr-)) that are deficient in dihydrofolate reductase (dhfr). Because they do not have dihydrofolate reductase, which will cause the inhibition of nucleic acid synthesis, they can only survive in a culture medium supplemented with hypoxanthine and thymidine (HT). However, the transfected plasmid (pPD-1-Fc) carries the dhfr gene, so successfully transfected cells can express dihydrofolate reductase and survive in the absence of HT. dhfr is a positive selection marker in the stable transfection of the plasmid into CHO (dhfr-) cells.
[0089] Three days after transfection, the culture medium was discarded, and the cells were washed twice with PBS to remove residual HT. The cells were digested with Trypsin and resuspended in 4 mL of IMDM (-HT) with serum; 3 mL + 33 mL IMDM was taken, 12 mL + 10 nm MTX was mixed and placed in P100 for culture, 12 mL -MTX was mixed and placed in P100 for culture, 12 mL + 10 nm MTX was mixed and plated in 96-well plates at 100 μL / well for culture, and 0.8 mL + 24 mL IMDM (-HT) was mixed and plated on a 96-well plate at 100 μL / well for culture. The purpose of culturing in P100 was to re-screen from P100 cells if clones with expression could not be obtained from the 96-well plate. One week later, the number of cell clones in each well was counted, and 80 μL / well of IMDM medium corresponding to the MTX pressure was added to each well. The cells in P100 were treated with medium replacement at the original pressure. After one week of continuous culture: 1. The cells in P100 were cryopreserved. 1. First, digest the cells in P100 according to the above method, and then resuspend the cells with 4mL of new IMDM (the amount of new culture medium used to resuspend the cells depends on the number of cells. Generally, 4 to 6 tubes of P100 can be frozen after the cells are fully grown, that is, resuspend with 4 to 6mL of new culture medium), then add DMSO at a ratio of 7.5%, blow and mix with a pipette, and then divide into 1mL / freezing tubes. According to the slow freezing principle, store at 4℃ for 30min, then transfer to -80℃, and then transfer to liquid nitrogen for long-term storage. 2. Collect the culture medium in the 96-well plate and use ELISA to determine the protein concentration (in this study, because the expressed recombinant protein is a secreted soluble protein, its expression can be detected by detecting the content of the target protein in the culture medium).
[0090] According to the ELISA test results, 8 cell clones with higher PD-1-Fc concentrations were selected from the 96-well plate and transferred to a 12-well plate for expanded culture. After a few days of culture, the cells in the 12-well plate were digested, counted with a V-cell, and the cell number was adjusted to 0.1 million / well. MTX was removed and cultured in a 6-well plate for a week. The recombinant protein concentration was then measured. According to the test results, 4 cell clones with high expression levels were selected and cultured in a six-well plate until cell clones with higher expression levels were obtained. Subsequently, the cell clones with higher expression levels were subjected to MTX pressure treatment to further increase protein expression.
[0091] The MTX pressurization method is used to achieve the increase in yield. Its principle is mainly to amplify the dhfr gene and drive the amplification of its upstream and downstream target genes. Methotrexate (MTX) is a folic acid analog and a competitive inhibitor of dihydrofolate reductase. It will hinder the synthesis of cell nucleic acids and cause cell death. When we add MTX to the culture medium and gradually increase the content of MTX, although most cells will die due to the obstruction of nucleic acid synthesis, a small number of cells will counteract the inhibitory effect of MTX by amplifying their own dhfr genes in large quantities, and at the same time drive the upstream and downstream genes of the dhfr gene, including the gene expressing the target protein, to amplify in large quantities, thereby achieving the purpose of increasing the expression of the target protein.
[0092] In this study, we used the following method to treat cells with MTX pressure: the PD-1-Fc picked out from the 96-well plate was digested and counted according to the above method, the cell density was adjusted to 2×103 cells / mL using IMDM medium with MTX pressure increased to 100 nM, 10 mL of cell suspension was placed in P100 and cultured in a cell incubator and the cell growth was observed from time to time under a microscope; after one week, the cells in P100 were treated with medium replacement. It was important to maintain the original MTX pressure when changing the medium and continue to culture in a 37°C incubator for one week; after about two weeks of pressure treatment, the cells' tolerance to the current MTX pressure had basically stabilized, the cells that were intolerant to the current MTX pressure had basically died, and most of the surviving cells were tolerant cells; the cells in P100 were digested and counted according to the above method, some of the cells were frozen for seed preservation as described above, and some were used in IMDM medium with MTX pressure increased to 500 nM. The cell density was adjusted to 2×103 cells / mL with M culture medium, 10 mL of the cell suspension was taken and cultured in P100, and the MTX pressure was continued to be increased according to the above method; after the pressure was increased to 500 nM and stabilized, the cell density was adjusted to 20 cells / mL and 100 μL / well was plated on two 96-well plates; one week later, the clone formation in each well of the 96-well plate was observed and recorded under a microscope, and 80 μL / well of the culture medium with the original pressure was added; after another week of culture, the culture medium in each well was collected to detect its OD450 activity, and 6 monoclonal clones with relatively high expression were selected and transferred to 12-well plates for expansion culture. For some of them, the cell density was adjusted to 0.1 million / well and MTX was removed and cultured in 6-well plates for one week, and then the PD-1-Fc concentration was measured. According to the measurement results, 4 cell clones with high expression were selected and cultured in six-well plates; the other part was gradually expanded and partially frozen.
[0093] 2.5. Serum-free culture of PD-1-Fc high-expressing cell lines
[0094] In the production process of fusion protein, suspension culture has the advantages of avoiding serum-derived contamination, high protein yield, easy batch production process, easy purification of cell products and low production cost, so we will perform serum-free acclimation culture on the high-expressing cell monoclones. We perform serum-free acclimation culture in the following way: take the high-expressing monoclonal cells of PD-1-Fc screened under the condition of adding MTX pressure to 500nM and culture them in a P100 cell culture dish. When the cell growth density reaches 80% to 90% and the condition is good, retain 1mL of the original serum IMDM culture medium in the P100 culture dish, add 9mL of serum-free culture medium SFM, and reduce the proportion of FBS in the culture medium to 1%; culture in a 37℃ cell incubator for 24h, observe the cell suspension and cell status, and retain 1mL of the original , add 9mL SFM, at which point the FBS ratio in the culture medium is reduced to 0.1%; culture in a 37°C cell incubator for 24 hours, shake the cells and culture medium in the culture dish, take 9mL to a sterile 15mL centrifuge tube, take 1mL from it for Vi-cell counting, and record the cell number and cell activity, adjust the remaining cells to 0.25-0.5×106 / mL, 6mL / 50mL centrifuge tube, place on a 37°C, 5% CO2 incubator shaker at 180rpm / min for suspension culture; repeat the above operation. Note that during the serum-free acclimation culture process, the P100 culture dish always maintains a 500Nm MTX pressure, and the suspension cultured cells reduce the MTX to the most appropriate concentration according to the actual situation of the cell adaptation to MTX after suspension. The cells in the centrifuge tube need to be counted every day. If the cell density reaches 2×106 cells / mL, pass it to 0.25-0.5×106 cells / mL. When the cell number can double normally every day and the cell activity is good, the culture can be continued in SFM. When the cell density reaches about 2×106 cells / mL, adjust the cell number to 10×106 cells / mL, add 7.5% dimethyl sulfoxide (DMSO), pipette and mix, 10×106 cells / mL / tube, and transfer to liquid nitrogen for storage.
[0095] 2.6.PD-1-Fc fusion protein production
[0096] The PD-1-Fc CHO cells obtained by the above serum-free acclimation culture were revived in the SFM medium maintaining the original MTX pressure, and suspended and cultured at 37°C and 180rpm / min. When the cell density reached 2×106cells / mL, MTX was removed and the cell density was adjusted to 0.5×106cells / mL, 6mL / 50mL centrifuge tube, and the day of culture was recorded as day0; thereafter, samples were taken and counted every day to monitor the cell growth status and samples were retained for future detection and comparison; when the cell density reached 2×106cells / mL, 5% (volume ratio) of 15% Logicfeed2# or 10% (volume ratio) Logicfeed5# with a concentration of 3.5% (feed supplementation method is to supplement every other day), and additionally add glutamine (Gln) with a final concentration of 4mM (Gln supplementation method is to supplement for three consecutive days, with a final concentration of 4mM on the first day and a final concentration of 2mM on the second and third days); when the cell density reaches 4×106cells / mL, the incubator temperature is lowered to 32°C, and then the volume ratio of 15% Logicfeed2# or 3.5% Logicfeed5# is reduced to 2.5% and 5% respectively, and the feed supplementation method is as follows Figure 5 shown.
[0097] After optimizing the feed conditions, the PD-1-Fc / CHO cells obtained by the above serum-free acclimation culture were revived in 30 mL of the optimal culture medium under the original MTX pressure, and suspended and cultured at 37°C and 120 rpm / min until the cell density reached 2×106 cells / mL. The cells were then placed in 270 mL of the optimal culture medium to adjust the cell number to 0.5×106 cells / mL, and suspended and cultured at 37°C and 120 rpm / min, and the day was recorded as Day 0. Samples were taken daily to monitor the cell growth status, and the feed was supplemented according to the optimized feeding conditions. The production was terminated when the cell activity dropped to 90% or about Day 10, and the cell culture fluid was collected, and the supernatant was collected by centrifugation at 3500 rpm and 5 min, and filtered with a 0.2 μm filter membrane to remove impurities such as residual cell debris in the sample to avoid clogging the purification column during purification, and frozen at -80°C for use.
[0098] After the process, the small samples taken every day were tested by SDS-PAGE: the samples collected during the process were centrifuged at 3500rpm for 5min, 15μL of the sample was taken into a clean 0.5mL centrifuge tube and 15μL of 2×sample loading buffer was added, and the mixture was mixed by flicking with fingers, and then centrifuged at 2000rpm for 2min; the sample was boiled at 100℃ for 5min in a water bath, and then centrifuged at 2000rpm for 2min. 20μL / well of the processed sample was added to the 10% polyacrylamide gel well and electrophoresis was started; when the sample was in the concentrated gel, the reducing gel used a constant voltage of 70V, while the non-reducing gel used a constant voltage of 80V. When the protein indicator Markers entered the separation gel, the reducing gel used a constant voltage of 100V, while the non-reducing gel used a constant voltage of 120V; after the electrophoresis was completed, the concentrated gel was cut off, and the Coomassie brilliant blue dye was used to stain overnight on a shaker, and the next day it was destained, and the results were scanned and saved on a gel imager.
[0099] From the cell growth curve, it can be seen that during the process, the cell density of the feed5# group was greater than that of the feed2# group. The maximum cell density of PD-1-FC was 7.34×106cells / mL, while the maximum cell density of the feed2# group was 4.85×106cells / mL. From the perspective of cell density alone, the feed5# was superior to the feed2# ( Figure 6 A); From the perspective of cell activity, there was no significant difference between the Feed2# group and the Feed5# group ( Figure 6 B); From the perspective of yield, the yield of PD-1-Fc is better in Feed2# than in Feed5# ( Figure 6 C, D), so we chose Logic feed2# for the later production of target protein.
[0100] Based on the above experimental results, we selected SFM medium and Feed2# to produce the target protein. Figure 7 As shown: the highest PD-1-Fc cell density reached 6.89×106cells / mL, and the cells were in good condition throughout the production process; the production of the target protein was detected by SDS-PAGE, and it can be seen that the production of PD-1-Fc fusion protein increased with time.
[0101] Figure 7:PD-1-Fc Process in SFM with Logicfeed2#:Cell growth curve (A) and activity curve (B) during PD-1-Fc Process, SDS-PAGE detection of target protein production changes during PD-1-Fc Process (-me) (C), SDS-PAGE detection of target protein production changes during PD-1-Fc Process (+me) (D).
[0102] 2.7. Protein A affinity chromatography purification of PD-1-Fc fusion protein
[0103] The C-terminus of PD-1 protein carries an Fc tag, which can be purified by affinity chromatography using a protein A affinity chromatography column. According to the HiTrapTM MabSelectTM SuRe (1 mL) filler loading, 25 mL of the target protein culture medium is filtered through a 0.2 μm filter head and then purified by affinity chromatography. The purification steps of the AKTA prime plus system are as follows:
[0104] 1) Balance
[0105] Turn on the AKTA prime plus system. After the system completes self-check, rinse pump A with WFI water and place it in the equilibration buffer. Set the flow rate to 1 mL / min and the protection pressure to 0.5 MPa. Click the OK button to run the system. When the entire pipeline is filled with equilibration buffer, connect the 1 mL HiTrapTM MabSelectTM SuRe prepacked column to the AKTA system. The equilibration steps are: equilibration buffer rinse (5 CV, 1 mL / min) → CIP buffer (5 CV, 1 mL / min) → pause for 30 min → CIP (5 CV, 1 mL / min) → equilibrate the column with equilibration buffer (5 CV, 1 mL / min).
[0106] 2) Sample loading
[0107] Click the pause button to pause the AKTA prime plus system, replace pump A with the cell culture medium, set the loading flow rate to 1 mL / min, click the pause button to start the AKTA prime plus system, and start loading the sample. When the ultraviolet absorption (UV) value of the detector reaches 50 mAu, it indicates that the sample begins to flow out of the column.
[0108] 3) Rebalancing
[0109] When the sample is loaded to about 22 mL, click the pause button to pause the AKTA prime plus system, replace pump A with the equilibration buffer, and click the pause button to flush with the equilibration buffer until the detector UV value reaches 0.
[0110] 4) Elution
[0111] Click the pause button to pause the AKTA prime plus system, replace pump A with citric acid + NaCl elution buffer at pH = 3.0, set the elution flow rate to 1 mL / min, click the pause button to run the system, and when the UV value of the detector begins to increase, collect the eluate at 1 mL / tube (add 200 μL 150 mM Tris-HCL, pH = 8.5 to the collection tube in advance) until the UV value drops below 50 mAu. After the elution is completed, seal the chromatography column with 20% ethanol. Transfer the collected eluate to an Amicon Ultra ultrafiltration tube (Millipore, 50 kD), ultrafilter and concentrate into PBS buffer, and store it in aliquots at -80°C for later use. Take 10 μL of the purified stock solution and the purified sample, respectively, and separate them in 10% SDS-PAGE gel electrophoresis and analyze them by Coomassie Brilliant Blue staining. The results of Coomassie Brilliant Blue staining analysis show that the target protein with Fc tag in the cell culture medium can be recovered with high purity by elution from the protein A affinity chromatography column ( Figure 8 ).
[0112] Figure 8 Affinity chromatography purification and post-purification detection of PD-1-Fc and PD-L1-Fc Protein A: (A) PD-1-Fc Protein A purification chromatogram, where the arrow indicates the elution peak of the target protein; (B) SDS-PAGE detection of the purification effect of PD-1-Fc.
[0113] 2.8. Determination of PD-1-Fc purified protein concentration by BCA method
[0114] 1) Preparation of BSA standard curve
[0115] According to the instructions of the Thermo BCA protein quantitative analysis kit, add the corresponding volume of 0.9% NaCl and the corresponding volume of the corresponding concentration of BSA standard to the 96-well non-detachable ELISA plate in the order in the table; add Reagent A and Reagent B to the centrifuge tube at a ratio of 50:1, invert and mix, and pour into the sample tank; use an 8-hole gun to quickly add 200μL / well of working solution to each well; place the 96-well plate on the float plate in a 37°C water bath for 30 minutes; after cooling, read the absorbance of each well at 570nm on the ELISA instrument. With the final concentration of BSA as the X-axis and the corresponding OD570 reading as the Y-axis, a second-order polynomial is used to calculate and prepare the BSA concentration standard curve, and the determination coefficient R2 is obtained. When R2 ≥ 0.99, the measurement result is considered valid. Then, with the OD570 reading as the X-axis and the final concentration of BSA (mg / mL) as the Y-axis, a second-order polynomial is used to draw a standard curve to obtain the regression equation. The reaction system of the BSA concentration standard curve is as follows: Fig. 9 shown.
[0116] 2) Sample concentration determination
[0117] According to the above method, the sample to be tested is diluted with the corresponding buffer to the range of the standard curve, and the diluted sample to be tested is added to the corresponding position in the 96-well plate, 20 μL / well, and 2 replicates are made for each sample, and the corresponding buffer is used as a blank control; the OD570 reading is substituted into the regression equation in (1) to calculate the protein concentration of the sample to be tested.
[0118] 2.9. SEC-HPLC to detect the purity and molecular weight of PD-1-Fc
[0119] Turn on the power of the Agilent 1260 infinity workstation and 1200LC modules. After the workstation system is tested, enter the software operation interface, set the guard column pressure to 120 bar, the flow rate to 0.2 mL / min, gradually increase the flow rate to 1 mL / min, and the detection wavelength to 280 nm. When the bubbles in the pipeline are completely removed, connect the TSK gel guard column SWxL (6.0×40 mm) guard column and TSK gel G3000 SWxL (7.8×300 mm) chromatographic column to the pump and DAD detector, turn on the UV lamp at the same time, and use PBS filtered by a vacuum pump and ultrasonically treated for 30 minutes as the mobile phase to flush the baseline to a flat level, with a flow rate of 1 mL / min.
[0120] The PD-1-Fc fusion protein purified by Protein A affinity chromatography was diluted to 1.0 mg / mL with PBS filtered by a 0.22 μm needle filter, and then mixed with the protein molecular weight standard sample and centrifuged at 13200 rpm for 5 min in a refrigerated centrifuge. 20 μL of the sample was taken and placed in the loading inner insert tube; after the inner insert tube was placed in the sample bottle, the sample bottle was placed in the corresponding position in the sample tray of the injection system for automatic loading. The detection time for each sample was 20 min.
[0121] After the test, the pump tube was switched from PBS to 20% ethanol, and the flow rate of the pump was gradually reduced from 1mL / min to 0.2mL / min. After flushing overnight, the chromatographic column and the guard column were filled with 20% ethanol solution. The chromatographic column and the guard column were removed in turn and stored in a 4°C refrigerator; the offline analysis software was opened, and the data printing interface was entered to analyze the protein purity; a protein molecular weight standard curve was made according to the peak time of each molecular weight protein of the protein molecular weight standard, and the approximate molecular weight of PD-1-Fc was calculated according to the molecular weight standard curve and the peak time. The SEC-HPLC experimental results show (such as Figure 1-6 ), the molecular weight of the protein was roughly estimated by comparing the peak time of the molecular weight standard with the peak time of the sample to be tested. The main peak time of PD-1-Fc was 7.518min, and its molecular weight was estimated to be around 160kDa, with a purity of 97%. Therefore, the target protein with higher purity can be obtained through Protein A affinity chromatography purification, laying the foundation for subsequent research.
[0122] Fig.10 SEC-HPLC analysis of the molecular weight and purity of PD-1-Fc: (A) molecular weight standard, (B) SEC-HPLC detection of PD-1-Fc.
[0123] 2.10 In situ staining of tumor tissue
[0124] The paraffin sections of various tumor tissues were stained in situ using the target protein purified by Protein A affinity chromatography. The main steps are as follows:
[0125] 1) Heat the paraffin sections in a 65°C incubator for 2 hours, then dewax in xylene for 15 minutes twice; then soak in 100%, 95%, 80%, and 70% alcohol for 2 minutes each; and wash with distilled water for 5 minutes twice.
[0126] 2) Treat the slices with 3% hydrogen peroxide (room temperature) for 25 min to block the action of endogenous catalase → wash thoroughly with distilled water (on a shaker) → wash with PBS for 5 min × 2 times;
[0127] 3) Directly add PD-1-Fc (2u / mL) onto the sliced tissue, incubate in a humidified box at 37°C for 30 min → rinse the tissue slices at room temperature with PBS for 5 min × 2 times;
[0128] 4) Add HRP Polymer (enzyme-labeled secondary antibody binds to Fc), incubate at room temperature for 30 minutes → rinse tissue sections in PBS at room temperature for 5 minutes × 2 times;
[0129] 5) DAB was evenly dropped on the coverslips of each well and placed in a 37°C oven for reaction;
[0130] 6) When the coverslips of the experimental group are brown-yellow and the cell surface is stained to a certain extent under a microscope, wash away the residual DAB on the coverslips with purified water; seal the slides with neutral gum and observe under a light microscope.
[0131] In the in situ receptor binding test, the tumor cell membrane on the tumor section incubated with PD-1-Fc is stained with the Fc-bound secondary antibody substrate DAB due to the presence of PD-L1. The score is 0 to 3 points according to the depth of the staining reaction and the number of positive cells, where the depth of staining is based on the color reaction of the majority of cells. Light yellow is 1 point, brownish yellow is 2 points, tan is 3 points, and no staining is 0 points. The number of positive cells ≤ 10 is 0 points, 11-45% is 1 point, 46-70 is 2 points, and >70 is 3 points. It is divided into 4 levels according to the integral scores of these two indicators, that is, negative (-) is 0 points, weak positive (+) is 2 points, positive (++) is 3 to 4 points, and strong positive (+++) is 5 to 6 points. Positive and strong positive are regarded as high expression of PD-L1, weak positive is regarded as low expression, and negative is regarded as no expression. In the staining of each tumor tissue, such as Figure 11-Figure 15 shown.
[0132] It should be noted that, in this article, relational terms such as first and second, etc. are only used to distinguish one entity or operation from another entity or operation, and do not necessarily require or imply any such actual relationship or order between these entities or operations. Moreover, the terms "include", "comprise" or any other variants thereof are intended to cover non-exclusive inclusion, so that a process, method, article or device including a series of elements includes not only those elements, but also other elements not explicitly listed, or also includes elements inherent to such process, method, article or device.
[0133] Although embodiments of the present invention have been shown and described, it will be appreciated by those skilled in the art that various changes, modifications, substitutions and variations may be made to the embodiments without departing from the principles and spirit of the present invention, and that the scope of the present invention is defined by the appended claims and their equivalents.
Claims
1. A pathological method for in situ detection of PD-L1 expression in tumor tissue, characterized in that: The following steps are involved: Sequence synthesis and sequencing; PD-1-Fc plasmid construction: Expression and identification of PD-1-Fc fusion protein: In situ staining of PD-L1 was performed using PD-1-Fc fusion protein in paraffin tissues collected from various tumors.
2. A pathological method for in situ detection of PD-L1 expression in tumor tissue according to claim 1, characterized in that: The PD-1-Fc plasmid construction includes the following steps: PD-1 gene optimization and synthesis; Preparation of competent cells GH2; PD-1-Fc plasmid construction.
3. A pathological method for in situ detection of PD-L1 expression in tumor tissue according to claim 1, characterized in that: The steps of PD-1 gene optimization and synthesis include: The extracellular segment of the human PD-1 gene sequence is intercepted, including the start codon and signal peptide, but without the stop codon; According to the degeneracy of genetic codons, the sequence was optimized by mutation to meet the requirements of the Cricetulus griseus (CHO) cell eukaryotic expression system for expressing AP fusion protein and to contain no commonly used restriction endonuclease sites; The KOZAK (5'-ACCCCGCCCGCCACC-3') sequence was inserted before the start codon ATG at the 5' end of the optimized PD-1 sequence, and the restriction endonuclease sites of HindⅢ (5'-AAGCTT-3') and BglⅡ (5'-AGATCT-3') were inserted at the 5' end and 3' end of the PD-1 sequence, so as to insert the PD-1 sequence into the Fc-Tag vector.
4. A pathological method for in situ detection of PD-L1 expression in tumor tissue according to claim 1, characterized in that: The preparation of competent cells GH2 includes the following steps: Take out E. coli GH2 from -80℃ and streak it on LB solid medium without resistance, and culture it in an adjustable constant temperature incubator at 37℃ overnight. The next day, pick a single colony and inoculate it in a 15mL centrifuge tube containing 5mL LB liquid medium without resistance, and culture it in a constant temperature shaking incubator at 37℃ and 220rpm for 16h; Take 3 mL of bacterial solution and inoculate it into 100 mL of LB liquid medium without resistance. Incubate the culture in a constant temperature shaking shaker at 37°C and 220 rpm until the absorbance of the bacterial solution at 550 nm is 0.5-0.
6. After cooling on ice for 10 min, centrifuge at 4°C and 4000 rpm for 10 min and discard the supernatant. Add 7.5 mL of pre-cooled 0.1 M MgCl2 solution to stop the bacterial solution, resuspend it, centrifuge it at 4000 rpm for 10 min at 4°C, and discard the supernatant. Add 5 mL of pre-cooled 0.1 M CaCl2 solution to stop the bacterial solution, resuspend and place on ice for 20 min, then centrifuge at 4°C, 4000 rpm for 10 min, and discard the supernatant; Add 17.2 mL of pre-cooled 0.1 M CaCl2 solution, ice bath for 30 min, then add 5 mL of pre-cooled 50% glycerol, pipette and mix thoroughly, then dispense 200 μL / tube into sterilized 0.5 mL centrifuge tubes, immediately immerse in liquid nitrogen, and store at -80°C after it is completely frozen.
5. A pathological method for in situ detection of PD-L1 expression in tumor tissue according to claim 1, characterized in that: PD-1-Fc plasmid construction includes: The pUC57-PD-1 glycerol bacteria obtained after gene synthesis were streaked on LB solid medium with ampicillin resistance (A+) and tetracycline resistance (T+), and cultured in an adjustable constant temperature incubator at 37°C overnight. The next day, a single colony was picked and inoculated into a 15mL centrifuge tube containing 5mL of non-resistant LB liquid medium, and cultured in a constant temperature shaking shaker at 37°C and 220rpm for 16h; before plasmid extraction, the strain was preserved, added into a 1.5mL centrifuge tube at a ratio of 50% glycerol: bacterial solution = 3:1, mixed (50% glycerol 300μL, bacterial solution 100μL), sealed with a sealing film, and stored at -80°C; Centrifuge the remaining bacterial solution at 13400rpm for 1min in a 1.5mL centrifuge tube and discard the supernatant; then add 250mL solution / RNAse A (Omega) and vortex to resuspend the bacterial solution, then add 250μL SolutionⅡ to the above mixture and gently invert 4 to 6 times. This step should not exceed 5min; continue to add 350μL SolutionⅢ, gently invert several times until a white flocculent precipitate is formed, and then centrifuge at 13400rpm for 10min; transfer the upper clear liquid to a HiBind DNA binding column with a 2mL collection tube, centrifuge at 13400rpm for 1min, discard the filtrate in the collection tube, and re-install it with the HiBind DNA binding column; add 500μL HB Buffer, centrifuge at 13200rpm for 1min, discard the filtrate in the collection tube, and re-install it with the HiBind DNA binding column; add 700μL Wash Buffer, 13400rpm, 1min chamber centrifugation, discard the filtrate in the collection tube, and reassemble it with the HiBind DNA binding column, repeat this step once; install the HiBind DNA binding column on the collection tube, spin at 13400rpm for 2min, open the lid and let it air dry for 5min to evaporate the ethanol in it; then install the HiBind DNA binding column in a clean 1.5mL centrifuge tube, add 50μL of 65℃ preheated sterile water, centrifuge at 13200rpm, 1min, elute the DNA; measure the OD260 of the plasmid by UV spectrophotometer and calculate the concentration of the plasmid by the ratio of OD260 / OD280; Take 1 μg of the obtained PD-1 plasmid and add it to a PCR tube, add HindIII and BglII restriction endonucleases, 10×KBuffer, and then add sterile water to make up to 50 μL of the reaction system, and perform double enzyme digestion in a 37°C constant temperature water bath for 2 hours; The digestion products were separated by 2% agarose gel electrophoresis, and then the PD-1 (522 bp) and PD-L1 (747 bp) target band gels were cut with a blade under the irradiation of an ultraviolet analyzer and placed in a sterile 1.5 mL centrifuge tube. The PD-1 target fragment was recovered according to the instructions of the Omega gel recovery kit: the target band gel was placed in a sterile 1.5 mL centrifuge tube and weighed (in milligrams), and Binding buffer was added at a ratio of 1:1, and the mixture was placed in a 60°C water bath until it was completely melted; then the liquid was transferred to a HiBind column, centrifuged at 13400 rpm for 1 min, and the filtrate was discarded; then 700 μL SPW buffer was added to the HiBind column, and after standing at room temperature for 2 to 3 minutes, the column was centrifuged at 13400 rpm for 1 min, and the filtrate was discarded, and this step was repeated once; then the column was spun at 13400 rpm for 2 minutes; then the HiBind column was transferred to a 1.5 mL centrifuge tube, and 20 μL Preheat sterilized water at 60℃, centrifuge at 13400rpm for 1min, repeat the operation with 10μL preheated sterilized water at 60℃, collect the filtrate as the DNA solution, and then use agarose gel electrophoresis to detect whether the target fragment is successfully recovered; at the same time, take 1μg of pFc-Tag vector, add HindIII and BglII restriction endonucleases, 10×K Buffer, and add sterilized water to make up to 20μL reaction system, and perform double enzyme digestion in a 37℃ constant temperature water bath for 2h; Add sterile water to the above Fc-Tag digestion product to a total volume of 30 μL, then add an equal volume of phenol / chloroform mixture (phenol 3:1 chloroform), vortex for 15 seconds, ice bath for 5 minutes, centrifuge at 4°C 13200 rpm for 5 minutes, carefully pipette the supernatant into a new sterile 0.5 mL centrifuge tube; add 3 μL 3M sodium acetate solution and 5 μL 10mg / ml glycogen, flick with fingers to mix, then add 180μL pre-cooled anhydrous ethanol, vortex for 15s, and place at -80℃ for 2h; then, discard the supernatant; then carefully adhere to the wall and add 200μL pre-cooled 85% ethanol solution, ice bath for 5min, centrifuge at 4℃ 13200rpm, 1min, discard the supernatant, open the lid and stand on ice for more than 1min to allow the ethanol to evaporate; then add 30μL sterile water to dissolve the precipitate; take the gel recovery fragment of PD-1 and the Fc-Tag vector purification product obtained by phenol / chloroform purification, add them to the connection system at a volume ratio of 16:1, and connect the target fragment and the vector overnight at 16℃ using T4 ligase (Takara); Take out 200μl E.ColiGH2 competent cells from the -80℃ refrigerator and thaw on ice; after it is completely thawed, add 20μL of the ligation product, mix it with a pipette, and then place it in an ice bath for 30-60min; heat shock the mixture in a 42℃ water bath for 90s, and then place it in an ice bath for 3min; add 800μl of LB liquid culture medium without resistance, and culture it in a constant temperature shaking shaker at 37℃ and 220rpm for 1h; take out the bacterial solution, centrifuge it at 5000rpm for 5min, discard 800μL of supernatant, resuspend the bacteria with the remaining supernatant, and then evenly apply it on the LB (A+, T+) double-antibody solid culture plate, and culture it upside down at 37℃ in an adjustable constant temperature incubator for 16-18h; Take 30 μL of bacterial lysate and add it to a 0.5 mL centrifuge tube; then use a sterile gun tip to stick a small amount of bacterial monoclonal, put it into the bacterial lysate and repeatedly blow and mix; then put it in boiling water for 5 minutes, take it out and centrifuge it at 13200 rpm for 2 minutes, and take 1 μL of supernatant as a template for colony PCR; the upstream primer uses the primer L-Fc on the pFc-Tag vector: 5'-GAACCCACTGCTTACTGGCT-3', and the downstream primer uses the primer R-Fc on the pFc-Tag vector: 5'-TCAGGGTCTTCGTGGCTCACG-3', which are the sequences on the Fc-Tag vector located upstream and downstream of the PD-1 insertion point; The PCR products were separated by 2% agarose gel electrophoresis. The target bands appeared at about 500 bp for PD-1-Fc and about 750 bp for PD-L1-Fc, which were regarded as positive clones. A small amount of the bacterial monoclonal colonies were streaked on the LB (A+, T+) double-antibody solid culture plate with a sterile gun tip, and cultured in an adjustable constant temperature incubator at 37°C for 16 to 18 hours; then a single clone was picked from the culture dish and inoculated into LB (A+, T+) double-antibody liquid culture medium for expansion culture, and cultured overnight in a constant temperature shaking incubator at 37°C and 220 rpm; then the plasmid was extracted according to the method provided by Omega's plasmid extraction kit; 1 μg of the extracted pPD-1-Fc plasmid was added to HindIII and BglII restriction endonucleases, 10×K Buffer, and then sterilized water was added to make up to 20 μL of the reaction system, and double enzyme digestion was performed in a 37°C constant temperature water bath for 2 hours; the digestion products were separated by 2% agarose gel electrophoresis, and whether the bacterial clone was positive was further determined by whether the target band of known size was cut out, and the plasmid judged to be positive was sent for gene sequencing; The PD-1 / PD-L1 fragment obtained by optimized synthesis, enzyme digestion and gel recovery purification was inserted into the Fc-Tag vector through the two enzyme sites of HindⅢ and BglⅡ to construct the expression plasmid pPD-1-Fc / pPD-L1-Fc.
6. A pathological method for in situ detection of PD-L1 expression in tumor tissue according to claim 1, characterized in that: The PD-1-Fc fusion protein expression comprises the following steps: Subculture of CHO host cells; 293T host cell subculture; Plasmids were stably transfected into CHO (dhfr-) cells and transiently transfected into 293T cells; Screening of cell lines with high expression of PD-1-Fc; Serum-free acclimation and culture of PD-1-Fc high-expressing cell lines; PD-1-Fc fusion protein production; PD-1-Fc fusion protein Protein A affinity chromatography purification; The concentration of purified PD-1-Fc protein was determined by BCA method; SEC-HPLC detection of PD-1-Fc product purity and determination of molecular weight In situ staining of tumor tissue.
7. A pathological method for in situ detection of PD-L1 expression in tumor tissue according to claim 1, characterized in that: The steps of subculturing CHO host cells include: CHO host cells were cultured in IMDM medium with serum; CHO (dhfr-) cells were revived, subcultured and plated.
8. A pathological method for in situ detection of PD-L1 expression in tumor tissue according to claim 1, characterized in that: The steps for stable transfection of plasmids into CHO (dhfr-) cells and transient transfection into 293T cells include: Observe the growth of cells in the 6-well plate and remove 1 mL of old culture medium; Preheat serum-free IMDM medium at 37°C, place FuGENE6 transfection reagent at room temperature, and flick with fingers to mix; take a 1.5mL sterile centrifuge tube, add 600μL serum-free IMDM medium and 18μL FuGENE6 to it, flick with fingers to mix, and place at room temperature for 5 minutes, then divide it evenly into 6 1.5mL sterile centrifuge tubes, add 1μg of pPD-1-Fc plasmid to be transfected to each of 3 centrifuge tubes, and do not add plasmid to the remaining 3 tubes as the control group, flick with fingers to mix, and let stand at room temperature for 20 minutes; The plasmid mixture was added to 6-well plates respectively. One tube of the mixture containing pPD-1-Fc or not containing plasmid was added to the 6-well plate paved with CHO (dhfr-), and the other tube was added to the 6-well plate paved with 293T. After shaking up and down and left and right crosswise to mix, the 6-well plate was returned to the incubator and cultured for 72 hours. After 72 hours, the culture medium of transiently transfected 293T was collected to detect the expression of fusion protein to determine whether the target protein was secreted in the culture medium.
9. A pathological method for in situ detection of PD-L1 expression in tumor tissue according to claim 1, characterized in that: The steps of serum-free acclimation and culture of the PD-1-Fc high-expressing cell line include: The PD-1-Fc high-expressing monoclonal cells screened under the condition of adding MTX pressure to 500nM were cultured in a P100 cell culture dish. When the cell growth density reached 80% to 90% and the cell condition was good, 1mL of the original serum-containing IMDM medium was retained in the P100 culture dish, and 9mL of serum-free medium SFM was added to reduce the proportion of FBS in the culture medium to 1%; the cells were cultured in a 37°C cell incubator for 24h, the cell suspension and cell status were observed, 1mL of the original culture medium was retained again, and 9mL of SFM was added. At this time, the FBS in the culture medium The ratio was reduced to 0.1%; cultured in a 37°C cell incubator for 24 hours, shaken the cells and culture medium in the culture dish, took 9 mL to a sterile 15 mL centrifuge tube, took 1 mL from it for Vi-cell counting, and recorded the cell number and cell activity, and the remaining cells were adjusted to 0.25-0.5×106 / mL, transferred to a 6 mL / 50 mL centrifuge tube, placed in a 37°C, 5% CO2 incubator shaker at 180 rpm / min for suspension culture; repeat the above operation; note that during the serum-free acclimation culture process, the P100 culture dish always maintains 500 Nm MTX pressure, the MTX concentration of the suspended cells is reduced to the optimal concentration according to the actual situation of the cells' adaptation to MTX after suspension; the cells in the centrifuge tube need to be counted every day, and if the cell density reaches 2×106 cells / mL, it is passed to 0.25-0.5×106 cells / mL; when the cell number can double normally every day and the cell activity is good, the culture can be continued to be expanded in SFM. When the cell density reaches about 2×106 cells / mL, the cell number is adjusted to 10×106 cells / mL, 7.5% dimethyl sulfoxide (DMSO) is added, pipetted and mixed, 10×106 cells / mL / tube is cryopreserved, and transferred to liquid nitrogen for storage.
10. The pathological method for in situ detection of PD-L1 expression in tumor tissue according to claim 1, characterized in that: In situ staining of tumor tissues includes the following steps: using the target protein obtained by Protein A affinity chromatography to perform in situ staining on paraffin sections of various tumor tissues. The main steps are as follows: 1) Heat the paraffin sections in a 65°C incubator for 2 hours, then dewax in xylene for 15 minutes twice; then soak in 100%, 95%, 80%, and 70% alcohol for 2 minutes each; and wash with distilled water for 5 minutes twice; 2) Treat the slices with 3% hydrogen peroxide (room temperature) for 25 min to block the action of endogenous catalase → wash thoroughly with distilled water (on a shaker) → wash with PBS for 5 min × 2 times; 3) Directly add PD-1-Fc (2u / mL) onto the sliced tissue, incubate in a humidified box at 37°C for 30 min → rinse the tissue slices at room temperature with PBS for 5 min × 2 times; 4) Add HRP Polymer (enzyme-labeled secondary antibody binds to Fc), incubate at room temperature for 30 minutes → rinse tissue sections in PBS at room temperature for 5 minutes × 2 times; 5) DAB was evenly dropped on the coverslips of each well and placed in a 37°C oven for reaction; 6) When the coverslips of the experimental group are brown-yellow and the cell surface is stained to a certain extent under a microscope, wash away the residual DAB on the coverslips with purified water; seal the slides with neutral gum and observe under a light microscope.
